Download pdf - Academic OneFile - Document - Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors.pdf

4/26/2015 AcademicOneFileDocumentAntidepressantcoincidentmaniainchildrenandadolescentstreatedwithselectiveserotoninreuptakeinhibitors

http://go.galegroup.com.vlib.interchange.at/ps/retrieve.do?sgHitCountType=None&sort=RELEVANCE&docType=Report&prodId=AONE&tabID=T002&se 1/17

Title:AntidepressantcoincidentmaniainchildrenandadolescentstreatedwithselectiveserotoninreuptakeinhibitorsAuthor(s):MeganFJoseph,JairCSoaresandEricAYoungstromSource:FutureNeurology.4.1(Jan.2009):p87.DocumentType:ReportDOI:http://dx.doi.org.vlib.interchange.at/10.2217/14796708.4.1.87Copyright:COPYRIGHT2009FutureMedicineLtd.http://www.futuremedicine.com/loi/fnlFullText:

Author(s):MeganFJoseph1,EricAYoungstrom[[dagger]]2,JairCSoares3

Keywords

adolescentsantidepressantchildrencitalopramfluoxetineinducedhypomaniainducedmaniaparoxetinesertralineSSRIswitchvenlafaxineyouth

Theincreasinguseofselectiveserotoninreuptakeinhibitors(SSRIs)totreatchildrenandadolescentswithpsychiatricdisordershascausedconsiderablecontroversy[1].Theuseofantidepressantsinyouthstripledbetween1987and1996,withratesofprescriptionrisingfromthreeper1000totenper1000childrenandteenagersand21per1000youthsinthe1518yearoldrange[2].AlthoughsomeSSRIshavedemonstratedefficacyundercontrolledconditionsinrandomizedclinicaltrials[3,4],thereisevidencethatmanyofthesedrugsmaynotbeefficaciousingeneralclinicalsettings[57].Thepotentialbenefitofantidepressanttreatmentneedstobeweighedagainstthepotentialcostsandriskswhendecidingwhethertoprescribe[8].PerhapsthemostsalientconcernisthedebateoverwhetherSSRIscausesuicidalideationorbehaviorinadolescents[9].Althoughtherelativeriskofsuicidewhentakingantidepressantsissmall,suicideissuchaseriousoutcomethatthishasledtotheUKrestrictingtheuseofantidepressantsinchildrentofluoxetineincombinationwithcognitivebehavioraltherapy[10].AnadditionalpointofconcernthathasreceivedlessattentionintheliteratureisthequestionofwhetherSSRIsmayinducemaniaorhypomaniainchildrenandadolescents.Currentevidencesuggeststhatthisisatopicworthyoffurtherempiricalstudy[11],aswellasoneofsignificantclinicalconcern[12,13].Althoughmaniaisalesssevereoutcomethansuicide,itmaybeamuchmorecommonadverseevent,suggestingthatthepublichealthburdencouldbesimilar.

Thereareimportantreasonstofocusonreviewingtherelationshipofantidepressantsandmaniainyouths.AlthoughthereisasubstantialbodyofliteraturesuggestingthatantidepressanttreatmentwithSSRIscancauseanaffectiveswitchtomaniaorhypomaniainadults[1417],comparativelylittleisknownaboutthisphenomenoninchildrenandadolescents.Importantly,epidemiologicalevidencesuggeststhatthereisanegativecorrelationbetweenageandriskforantidepressantinducedmania[18].Putanotherway,theriskofinducingmaniawithantidepressantmedicationmaybeespeciallyhighforchildrenandadolescents14yearsoldandyounger[19].Youngerageatfirsttreatmentforbipolardisorderhasalsobeenreportedasapredictorofvulnerabilitytoantidepressantinducedcycleacceleration[20].

Severalfactorsmakeitchallengingtodrawfirmconclusionsbasedontheliteratureregardingantidepressantsandmania.Oneisthemethodologicalshortcomingsoftheliterature.Thedecisivedesigntoevaluatetheriskofantidepressantinducedmaniawouldbetotakeagroupofyouths,randomlyassignhalftoantidepressantsandhalftoplaceboandthenfollowthemoveralongtimeperiodtoevaluatetherelativeriskofdevelopingmaniawhiletakingantidepressants.Unfortunately,theavailablestudiesusingrandomandblindedassignmenthavenotusedstateoftheartassessmentformanicsymptoms,andthestudieswithbetterassessmenthaveusednonexperimentaldesigns.Additionally,severallimitationsprecludeusinglongitudinalrandomizedcontrolledtrial(RCT)designstoexaminethisissue,includingneedingaverylarge(ifnotprohibitive)samplesizeforadequatepowerandthepotentialethicaldilemmaofrandomizingadolescentstonoantidepressantsforalengthyperiodoftimewhensomebelievetheyareaneffectivetreatment.Asecondissueisthecomplexityofthepossiblerelationshipsbetweenantidepressantsandmania.Mostarticleshavenotdefinedaprioriconceptualmodelsortestedcompetingmodelsagainsttheevidence.Thisreviewwilldelineatesevendifferentconceptualmodelsthreeofwhichinvolveantidepressantshavinganiatrogeniceffect,twopertainingtothenatureofbipolardisorderandtwothataredrivenbyartifactsoftheassessmentprocess.Athirdissueisthat,intheabsenceofdecisivedataandanalyses,thepopularityofexplanationsandthechoicesmadebypractitionersaregoingtobedrivenbyfactorsbesidesevidence.Intheparlanceofthedecisionmakingliterature,weareforcedtorelyonheuristicstoguideourpractices,andthesemaybebiasedinpredictablewayssuchasoverestimatingrisks[21].

Thisreviewattemptstoaddressthethreechallengesby:

*RelyingonexplicitcriteriafromEvidenceBasedMedicine[28]forevaluatingthequalityofthestudiesprovidingevidenceaboutthepotentialassociationbetweenantidepressantsandmania



*Providingspecificconceptualmodelsoftherelationshipthatincludepotentialconfoundsaswellasharmfuleffectsofmedicationaspossibleexplanations

*Qualitativelyevaluatingtheevidencewithregardtoeachmodel

*Qualitativelydescribingtheprovocativenessofeachmodelorthedegreetowhichitmightcaptureattentioninbothclinicalandpopularaudiencesforreasonsbesidessupportingevidence

*Illustratingaquantitativeapproachforweighingthelikelihoodofhelpversusharm(LHH),againborrowedfromEvidenceBasedMedicine[28].

Thereviewcloseswithrecommendationsaboutimprovedassessmentstrategiesthatcanhelpmanagetheriskofmaniaduringtreatmentofdepression,aswellasinformingfutureresearchinthisarea.

Modelsoftherelationshipbetweenantidepressants&mania(&sevenpotentialpitfalls&remediesforpractitioners)

Thefollowingsectiondescribessevendifferentconceptualmodelsofthepossiblerelationshipbetweenantidepressantmedicationsandmanicsymptoms.Foreachmodel,thereisastatementaboutthepotentialassociatedpitfallsfromthevantageofthepractitioner,alongwithstrategiestoavoidoramelioratethepitfall.Eachmodelisalsoratedintermsofits'provocativeness',conveyingthedegreetowhichthemodelislikelytogainattentionowingtofactorsbesidesjusttheweightofevidencesupportingit.More'provocative'modelsarelikelytoplayuponfearofcausingharm(cognitivesciencehasdemonstratedthathumanbeingsgivegreaterweighttopotentialrisksthanbenefitsindecisionmaking)orasenseofscandal.Moreprovocativemodelswouldbeofconcerntopractitionersandwouldalsoreadilyattracttheattentionofmediaoutletsthatareperhapsfirstconcernedwithpopularappealabovescientificevidence.Conversely,lessprovocativemodelsmayhaveamoredifficulttimecapturingimaginationsandgainingbroaddissemination,eveniftheyhappentobeaccurate.Next,weevaluatethedegreetowhichthemodelinquestionissupportedbytheavailableevidence.Theratingsattachedtotheprovocativenessand'likelihood'obviouslyincludealargedegreeofsubjectivity.Wedonotpretendthattheyarecompletelyobjectiveorpreciseanddidnotrelyonformalcodingcriteria,butweintendthemtobeaconciseandclearwayofcommunicatingourimpressionsbasedonaqualitativereviewoftheliterature.Wealsowanttobeclearthattheterm'likelihood'isnotintendedtoconnoteanyformalstatementaboutprobability(i.e.,ascoreof6doesnotmeanthatthereisa6/7chancethatthetheoryiscorrect).Finally,wepresentsomepotentialresearchdesignsthatcouldmoreinformativelytesteachofthedifferentmodels.

Ignitionhypothesis

Uncoveringalatentdiathesis,turningongenesthatwerealreadypresent.Thetinderofbiologicalandenvironmentalriskfactorswerealreadypresentandtheexposuretothemedicationprovidedthesparknecessarytolightthebipolar'blaze'.TherehasbeenadramaticincreaseintherateofdiagnosisofbipolardisorderintheUSA[22,23],leadingtospeculationthatthehigherratesmay,inpart,beattributabletothehigherrateofmedicationprescriptionintheUSAignitingalargeramountofmaniainthepopulation[24].Potentialpitfall:selectinganagentthatisalogicalchoiceforthepresentingsymptomsbutdestabilizesthepatient.Remedy:carefulassessmentofriskfactors,carefulmonitoringofpossibleswitchorbreakthroughmaniaandrapidchangeinpharmacologyaftermanicsymptomsemerge.Provocativeness(17,with7beingthemostprovocative):5.TheIgnitionhypothesisisthescenariomostwidelydiscussedatmeetingsandinthepopularpressisthereasubsetofpatients(thosewithbipolardisorder)whoactuallyarelikelytobeharmedbyfrontlinetreatmentsfordepression?EuropeanregulatoryagenciesandothergroupsareconcernedthatthehigherratesofpediatricmaniaintheUSAmaybeatleastpartiallyattributabletothehighratesofexposuretomedication[24].Likelihoodbasedonavailableevidence:4.Informativewaytoevaluate:demonstrategenecompoundinteractions.Thishasnotyetbeendoneinpsychiatry,butcouldbeaccomplishedbyaddinggenotypingtoPhaseIIItrials,orbypersonalizedmedicinedataminingapproaches(comparingthegenomeagainsttreatmentadverseeffects).Forexample,workinTypeIIdiabeteshasrevealedgeneticpolymorphismsassociatedwithedema,orfluidretention,asideeffectofdrugtreatment[25].Studiessuchasthesefrombranchesofmedicineotherthanpsychiatrysuggestthatlinkinggeneticinformationwithmedicationsideeffectsispossible.However,duetolowbaseratesofmaniaasasideeffect,theseapproacheswouldrequirehugesamplesizes,thoughthesearebeingbuiltrapidly,andalsomoresystematiccodingofmanicsymptomsthanistypicallydone.Ideally,anypharmacogeneticresearchinthisareawouldalsotakeintoaccountenvironmentalfactorshowever,thisisdifficultonalargescaleandexamininggenebymedicationinteractionsmaybemorefeasible.

Scarhypothesis

Creatinganewdiathesisintheabsenceofpriorbiologicalrisk.Potentialpitfall:causingharmwithwellintentionedandlogicaltreatmentfordepression.Remedy:carefulassessmentofriskfactors,intensemonitoringtodetectemergentmania,andarapidswitchinpharmacology.Provocativeness:7.Thisisthescarymonsterlurkingintheclosetforprescribers.Takeonebrain,previouslyincapableofdevelopingmania,treatitfordepressionandleaveitpermanently



vulnerabletomanicepisodes.Likelihoodbasedonavailableevidence:2.Therearenodecisivestudiesrefutingthispossibility.However,therearemanyotherscenariosthatappearmuchmoreplausible,bothascausesofmanicsymptomsandalsobecausetheideathatbriefexposuretoacompoundcouldproducepermanentdeleteriouschangecontradictsgrowingknowledgeoftheplasticityoftheCNSanditstendencytosurviveandrecoverfrominsult.Informativewaytoevaluate:demonstratechangesinbrainmorphologyorpathophysiologyfollowingmedicationexposure,andshowthatthesepredictrecurrencesofmania.Itwouldbedecisiveifitcouldbedemonstratedthatthesechangesoccurafterexposuretothecompoundevenintheabsenceofestablishedgeneticriskfactorsforbipolardisorder.

Sideeffecthypothesis

Temporarydeleteriouseffectofthedrug,butnotatruemanifestationofabipolarillness.Potentialpitfall:theerrorwouldbeinattributingthesymptomstoadiseaseinsteadoftheimperfectdrug.Remedy:avoidlabelingpeoplewithmanicsymptomsoccurringwhiletakingantidepressantsashaving'bipolardisorder'.Atpresent,theDiagnosticandStatisticalManualofMentalDisordersIVTextRevision(DSMIVTR)indicatesthattheseeventsshouldbecodedas'substanceinducedmania'ratherthanaformofbipolardisorder[26]becauseofthepossibilitythatthesymptomsareasideeffectratherthananunmaskingofabipolardiathesis.Theclinicalmanagementtypicallywouldinvolvechangingpharmacotherapyandusingintensiveassessmenttoevaluatewhethermoodsymptomspersistataproblematiclevel.Provocativeness:3.TheSideeffectargumentmotivatedsomehighprofilelawsuitsbackwhencompoundswerefirstintroduced,butthisscenariohasdefinitelybeeneclipsedbytheIgnitionandScarhypothesesinrecentdiscussions.The'sideeffect'modelislessfrighteningbecauseitpositsthattheharmfuleffectsofthecompoundarelimitedinduration(orelseittransformsintotheScarHypothesis).Likelihoodbasedonavailableevidence:4.Informativewaytoevaluate:ABABdesign,alsoknownasachallengewithdrawalrechallengestudy,todemonstratethatsideeffectsonlyhappenwhenexposedtotheagent.TheSideeffecthypothesiswouldalsobesubstantiatedbyeithershowingthatmanicsymptomsoccurintheabsenceofgeneticriskforbipolardisorder,orbyshowingthatthepathophysiologyofsideeffectsisdifferentfromthepathophysiologyofbipolardisorder.

Vigilancehypothesis

Increasedmonitoringfortheillness,butnoactualchangeinrisk.TheVigilancehypothesisisavariantof'verificationbias',whichplaguesmedicalassessmentandrepresentsaseriousthreattothevalidityofanystudieswithoutblindedevaluationandastringentlydefinedcomparisongroup(ideallybasedonrandomassignment)[27,28].Potentialpitfall:confusingheightenedmonitoringwithincreasedrisk.Fallingvictimtoacognitiveheuristicandrememberingthecaseswheremaniaoccurred,butdiscountingthecaseswhereitdidnotoccurwhileusingantidepressants.Remedy:evaluateallpatientsonantidepressantsforpossibleemergenceofmanicsymptomsavoid'workup'bias.TheUSFDAnowrecommendsevaluationforpossiblebipolardisorderwhenprescribingantidepressantmedications,althoughthesuggestedlanguagecurrentlyfallsshortofa'blackbox'warning[101].PractitionerscanfindreviewarticlesandRCTsandlearnriskratesfromthem.Provocativeness:1.Thereisvirtuallynothingexcitingorglamorousaboutthevigilancescenario,anditisunpopulartoberemindedthatweareimperfectatweighingandcombininginformation[29].Likelihoodbasedonavailableevidence:5.Aswewillsee,studieswithstrongerdesignstendtofindlowerratesoftreatmentemergentmania.Additionalargumentsinfavorofthispossibilityare:first,theinaccuracyofmanyclinicaldiagnosesofbipolardisordersecond,theinadequacyofmanyclinicalevaluationsintermsofascertainingfamilyhistoryorpriorhistoryofhypomania[cf.30,31]andthird,thefailureofmostclinicianstoconsiderbipolardisorderasapossibilityinyouthsuntilrecently,andthewidelyunevenimplementationofconsistent,evidencebasedpracticesaroundthecountry,evenatpresent.Informativewaytoevaluate:researchstudyconductingsameintensityoffollowupforthoseexposedtoantidepressantsversusothercompounds,orsystematicallyvaryingtheintensityoffollowupforthesameantidepressantmedication.Presentingclinicianswithcasevignetteswherethecontextinwhichsymptomsarepresentedisvariedcouldalsobeinformative.Ideally,userandomassignmentandalargetrialtoequategroupsoncharacteristicsbesidescompound.

Medicationasirrelevanthypothesis

Whatwearewitnessingisthenaturalcourseofthebipolarillness,notaresponsetothetreatment.The'naturalcourse'confoundiswidelyrecognizedasarivalhypothesisinmethodologycirclesthatpotentiallyaffectsanydesignexceptforarandomizedtrial[32,33].Inthecaseofbipolardisorder,thepossibilitythatchangesinmoodareduetothenaturalcourseoftheillnessisnotavagueacademicpremiseitisawelldocumentedclinicalphenomenon.Potentialpitfall:blamingatreatmentforaneventthatwascompletelyunrelated.Remedy:findandrelyonwelldesignedresearchaboutriskstoavoidheuristicsandclinicalillusionsaboutclinicalphenomena.Provocativeness:1.Thereisnoelementofintrigue,noblametobeassignedtothecompoundorthepractitioner,exceptperhapsfailingtorecognizethe'greatmasquerade'ofmentalillnessinitsfirstguises.Likelihoodbasedonavailableevidence:6.Informativewaytoevaluate:combinestudieslookingatantidepressantcoincidentmania(ACM)incaseswithbipolardisorderrandomizedtoeitherantidepressantorplacebo(realistically,bothasadjuncttoanothermoodstabilizingcompound)thiswouldhelpruleoutacausalroleofthecompound.Goodepidemiologicalandnaturalhistorystudiesarealsoneededtounderstandratesofhypomania(sorelylackinginepidemiologicalstudies)andratesofrecurrence[cf.34].



Falsealarmshypothesis

Mislabelingjuvenilebehavioraspathologicalwhenitstillfallswithinnormallimitsmistakingaggressivebehaviorduetoothercausesaspediatricmania[35]oralternatively,mistakingthereturnofenergyandpositiveemotionsasdepressionliftsforhypomania.Potentialpitfall:attributingbehaviortoadiseasethatisnotpresent.Remedy:useassessmenttoolsthatextendbeyondtheroutineclinicalinterview,especiallytoolsthatrelyonagenormsordirectcomparisonstootherclinicalsamples.Adopt'probabilityofdiagnosis'approachfromEvidenceBasedMedicinetoacknowledgewhencasesareambiguousinsteadofclearcut[28].Provocativeness:6,ifyouareskepticalaboutthediagnosisofpediatricbipolardisorder2ifclinicallyactiveinthearea.TheFalsealarmhypothesisappealstothosereadytojumponthe'pathologizingchildhood'bandwagon[36],aswellasplayinguponconcernsabouttheoverdiagnosisofbipolardisorder[36].Thosewhoworkinclinicalsettingsorconductresearchwiththeseyouthsencountersevereenoughimpairmenttomakethe'justbeingakid'explanationimplausibleinmostcases.Likelihoodbasedonavailableevidence:2.Informativewaytoevaluate:muchworkhasbeendonevalidatingtheconstructofpediatricbipolardisorder[3739].Basedonthevaliditydata,itisclearthatatleastsomecasesofmaniareflectanunderlyingbipolarillness.Conversely,therearedefinitelycasesthatarelabeledandtreatedas'bipolar'whenitisacompletelydifferentprocessleadingtothesymptoms.Carefulindividualassessmentisthebestwayforward.

Bipolardepressionhypothesis

Earlyonsetdepressionisariskfactorforbipolardisorder[4042],andmanypeoplewithbipolardisorderfirstseektreatmentduringadepressedepisode[43,44].Thesefindingssuggestthatwhentreatingyouthsfordepression,weareoftendealingwiththedepressedphaseofwhatwillprovetobeabipolarillness.Potentialpitfall:blamingtreatmentforthenaturalcourseoftheillnessfailingtorecognizebipolardepression.Remedy:assessment,againcarefullyevaluatefamilyhistoryofbipolardisorder,assessforpriorhypomaniasormaniasassessformixedstates.Provocativeness:5.Theappealwouldcomefromthestealthfactor,thattheillnesshasbeenavoidingdetectionpreviously(contradictingcurrentconcernsaboutoverdiagnosisofbipolardisorder).Likelihoodbasedonavailableevidence:6.Informativewaytoevaluate:attheresearchlevel,studiesareneededthatcarefullyfollowchildrenandteenagerswithdepressionprospectively,tofindhowmanyofthemdevelophypomaniaormania.Thenextgenerationofresearchneedstoincorporatestrategiestoaccuratelydetecthypomania,whichhasbeentheAchillesheelofpriorresearch,leadingtotheambiguitiesforbipolarIIandcyclothymicdisorder.Asimilardegreeofsophisticationabouthypomaniaalsoneedstobedeployedinclinicaltrialsofantidepressants,especiallyplacebocontrolledstudies.

Guidelinesforevaluatingstudiesofharm

TherehasbeenamovewithinthefieldofEvidenceBasedMedicinetodevelopasetofguidelinesorcriteriaforevaluatingstudiesquickly,gaugingtheirdesignandappraisingtheirvalidityandrelevanceforindividualpatients.TheseincludetheConsolidatedStandardsofReportingTrials(CONSORT)criteria[32]forclinicaltrials,aswellasaseriesofbriefarticlesthatappearedasaseriesinJAMAbeforebeinganthologizedandexpanded[45].Perhapsthemostaccessiblediscussionoftheseguidelinesandtheirapplicationtoindividualcasesisofferedinthebook,'EvidenceBasedMedicine'[28].Ifantidepressantsdoinfactincreasetheriskofmania,itwouldbeanexampleoftreatmentcausingharm.Box1providesasetofcriteriaforevaluatingwhethertheevidenceaboutantidepressantscausingharminotherwords,inducingmaniaisvalid(adapted[28]).Wewillrefertothesecriteriawhenevaluatingthepublishedstudies.

Reviewoftheevidenceforantidepressantspotentiallyinducingmania

Antidepressantinducedmaniainadults

Antidepressantinducedmaniaisawellknownclinicalphenomenoninadults[14,15].Metaanalysissuggeststhatapproximately3.7%ofindividualswithunipolardepressionmayexperienceaswitchtomaniafollowingexposuretoaSSRI[46],while2444%ofindividualswithbipolardisordermayexperienceanaffectiveswitchwhiletakinganSSRI[17,47].Importantly,adults(andchildren)withbipolardisordertypicallyspendalargerpercentageoftimedepressedthanmanic/hypomanic[48,49],suggestingthattreatmentofdepressionmaybethemostimportantaspectofpsychopharmacologicalmanagementofbipolardisorder[11,50,51].

ManiacoincidentwithSSRIusageinyouths

ThenextportionofthereviewconcentratesontheliteraturepertainingtomaniaandSSRIsinyouths.WefocusedonSSRIsbecausetherelativelybenignsideeffectprofilehasmadethemalmostuniversallypreferredtothecyclicantidepressantsandmonoamineoxidaseinhibitorsinpediatricsamples[2,52].MedlineandPsycInfoweresearchedusingtheterms'childrenoradolescentsoryouth','mania','SSRI','inducedmania'and'antidepressantinducedmania'.Additionalreferencesweregatheredfromthereferencelistofidentifiedarticles.Thissearchstrategyidentified



36articlesforthereview.

CasestudiesofpediatricmaniacoincidentwithSSRIusage

TherearemanycasestudiesdescribingantidepressantinducedmaniainchildrenandadolescentstreatedwithSSRIs,includingcitalopram(fivecases)[53,54]fluoxetine(11cases)[5559]paroxetine(sevencases)[6063]sertraline(fivecases)[6467]andvenlafaxine(aserotoninnorepinephrinereuptakeinhibitoronecase)[69].Thesereportsdescribeayoungpersontreatedforanxietyordepression(andinonecase,epilepsy)[53],whodevelopedsymptomsofmaniaorhypomaniaaftertreatmentwithanSSRIforperiodsoftimethatweretypicallyshort(8weeksorfewer)[54,5662,6466]

,butweresometimeslong(from5monthstoayear)[53,57,58,63].Themediantimetoonsetofmaniawas21days,witharangefrom2to365days.Theseindividualsvariedintermsoffamilyhistory.Atotalof21%hadafirstdegreeorotherrelativewithdiagnosedbipolardisorder45%didnothaveafamilyhistoryofmooddisorders.

Theonsetofmania/hypomaniausuallyfollowedthecommencementoftheSSRI,butinsomecasesitwastheresultofanincreaseindoseafterthepatienttoleratedlowerdoses.Cessationofantidepressanttreatmentledtoaresolutionofthemanic/hypomanicsymptomsin59%ofcases,whileamoodstabilizerwasusedin38%ofthecasesinordertomitigatesymptoms[5355,57,59,62,65,67,68].Nearlyallcasestudiesreportedthatfollowingthecessationofthemanicsymptoms,thepatientthenremained'stable',typicallyoffoftheantidepressantorsometimesatalowerdosethepatientmayhavecontinuedonamoodstabilizerifonehadbeenadded.However,theperiodoftimeforwhichtheywerefollowedvariedamedianof20weekswitharangefrom2to52weeks.

Takenasawhole,thesecasestudieswouldseemtosuggestthatcautioniswarrantedwhentreatingchildrenandadolescentswithSSRIs,astherearedocumentedcasesofthistreatmentcoincidingwithmaniaorhypomania.However,itisalsoimportanttokeepinmindthatmooddisordersshownaturalfluctuations(withthe'Medicationasirrelevant'hypothesisrepresentingtheextremeviewthatwhatappearstobetreatmentemergentmaniaisactuallyjustabipolarillnessfollowingitsownnaturalcourse,independentofthepresenceorabsenceofantidepressantmedication),andthereforecausallinkstothedevelopmentofmanicsymptomsbytheadditionofanSSRI,orresolutionofmanicsymptomsbyremovaloftheSSRI,cannotbeestablishedbycasestudies.ThepharmacokineticsofantidepressantmedicationsmaketheuseofABABdesigns,whichcanbehelpfultoolsforestablishingcausalityorefficacyattheindividuallevel,difficultowingtothelonghalflivesandresultinglengthoftimeneededtotitrateorwashoutmedication.Additionally,casestudiesareprobablyabiasedsourceofinformation,astheyarewrittenaboutpatientswhostandoutintheclinician'smind.ReportsofyouthstreatedwithSSRIswhodonotdevelopmaniadonotappearintheresearchliteratureascasestudies.Thesameheuristicmayalsooperateattheleveloftheindividualclinician:itismuchmorememorablewhenacaseshowsanadverseeventsuchasmaniaversusacasethatdoesnotandhumansasdecisionmakersarepronetogivingmuchgreaterweighttonegativeeventsasanevolvedheuristicforavoidingrisks[69].

ChartreviewstudiesofSSRIinducedmania

SeveralchartorcasereviewshaveattemptedtoexaminetherelationshipbetweenSSRItreatmentandmaniainmoresystematicways.Somestudies'findingssuggestthatantidepressantsmightincreasetherateofmania.Faedda,Baldessarini,GlovinskyandAustinreportedarateof48.7%ofchildrenwithbipolardisorderdevelopingmaniafollowingtreatmentwithaSSRI(n=19of39exposed)[70].Theantidepressantinducedmanicepisodewastheepisodethatinitiatedthebipolardiagnosisinonly17%ofthosecases.Themedianlatencytomaniawas12.5days(acrossallclassesofantidepressantsandstimulants).AnotherchartreviewofyouthswithbipolardisorderrevealedthatthosereceivingSSRItreatmentwerethreetimesmorelikelytoreportmanicsymptomsattheirnextfollowupvisitthanyouthswhodidnottakeaSSRI[71].Wilensandcolleagues,whenreviewing82consecutiveadmissionstoapediatricpsychopharmacologyunitwhowereprescribedanSSRI,foundthatfiveoftheyouth(6%)haddevelopedmanicsymptomswhiletakingtheSSRI[72].Areviewof79consecutivehospitaladmissionsshowedthatyouthswhohadeverreceivedanantidepressanthadanearlierageofonsetofbipolardisorderthanyouthswhohadnot[73].However,thelatterstudydidnotlookattheeffectoftreatmentwithaSSRIseparatelyfromotherclassesofantidepressants.ThepatternoffindingsinthesestudiescouldbeexplainedbytheIgnitionorScarhypotheses,butitalsoisconsistentwiththeBipolardepressionhypothesis:youthswithbipolardisordermightoftenhaveearlieragesofonsetfortheirdepression,leadingtoearlierantidepressantprescription.Anotherchartreviewstudyexamined'druginducedbehavioraldisinhibition',andfoundthatratesincreasedsignificantlywithSSRIusage[74].Astrengthofthisstudywasthatitincludedobjectivebehavioralindicators,suchasnumberofseclusionsbutitisnotclearhowmuchoverlapthereisbetween'behavioraldisinhibition'andmania.

Apharmacoepidemiologicstudyofageeffects[18]examinedconversiontomaniainchildren,adolescents,andyoungadultswithanxietyornonbipolarmooddisorders.Theauthorsanalyzedmentalhealthoutpatientandpharmacyclaimsof87,920individuals,aged529years,overamedianof41weeks.Thestudyshowedanoverallprevalenceofmanicconversionof5.4%.Atotalof49%oftheconvertershadbeenexposedtoaSSRI.SSRItreatmentwasassociatedwithahazardratioof2.1,roughlyatwofoldincreaseintheriskofconversiontomania.Thiseffectsizeisconcerning,yetalso



smallenoughthatEvidenceBasedMedicineauthoritiespointoutthatitcouldbeentirelyattributabletoextraneousfactorsbesidesaniatrogeniceffect[28].TheauthorsreportedthatamongthosetreatedwithSSRIs,youthyoungerthan15yearsofagewereatanincreasedriskformania.Again,thisdesigncannotdistinguishbetweentheBipolardepressionhypothesisversusthethreeiatrogenicpossibilities.

Inoneofafewstudiesspecificallyexaminingantidepressantinducedmaniainyouthswithbipolardisorder,Baumeretal.foundthatamong52childrenandadolescentswithoratriskforbipolardisorder(operationalizedbyhavingaparentwithbipolardisorder),50%experiencedeitheranewmanicepisodeoraworseningofanexistingepisodeafterbeingtreatedwithvariedantidepressants,approximately80%ofwhichwereSSRIs,foranaverageof1.4years[11].Inachartreviewstudythatfollowedyouthsfor12monthsafterfirsthospitaladmissionforeitheramanicoramixedepisode,antidepressantusewasassociatedwitharecurrenceofamoodepisode[75].Thereportingofthisstudydidnotdifferentiatebetweenmanicversusdepressedrecurrence,though,andotheraspectsofthefindingsindicatethattreatmentrefractorinessofdepressionmightbeinfluencingresults.

Otherstudieshavefoundnoeffectofantidepressantsontheageofonsetofbipolarorthemanicsymptomsobservedinyouthswithbipolardisorder,includingretrospectiveinterviewreportaboutageofonsetandcurrentinterviewbasedmoodratingsinanoutpatientsetting[76].Similarly,Soutulloandcolleaguesfoundthatamonghospitalizedadolescentswithbipolardisorder,ahistoryofexposuretoantidepressanttreatmentwasnotassociatedwithamoreseverecourseofhospitalizationasmeasuredbylengthofstayinthehospital,numberof'asneeded'medicationsgiven,orseclusionandrestraintorders[77].Attheotherextreme,astudyofyouthswithpsychoticdepressionfoundthatantidepressantusewasassociatedwithafourfolddecreaseinriskofdevelopingmaniaoverthefollowupperiod,withcasesfollowedforaslongas2years[78].

Alongitudinalstudylookingatthedevelopmentofmaniainacohortofyouthsoriginallyidentifiedashavingattentiondeficit/hyperactivitydisorderbutnocomorbidmooddisorderisalsorelevant[79].Theyouthswereoriginallyascertainedasacomparisongroupforalongitudinalstudyofpediatricbipolardisorder,with6yearfollowupdataprovidingthebasisforanalysis.Basedonblindedinterviews,29%developedbipolarIwithelationorgrandiosity.Antidepressantusewasnotsignificantlyassociatedwithdevelopingmania.ThesefindingscouldbeconsistentwiththeBipolardepressionhypothesis:systematicallyexcludingcaseswithpediatricdepressionmayhaveeliminatedcasesinitiallyidentifiedasdepressedwhowouldlaterhavecycledintomania.Excludingthesemighthaveeliminatedtheartifactthatisinterpretedasshowinga'switch'tomaniainotherstudies.

Inshort,thechartreviewstudies(includingthosewithfollowup)havefoundinconsistentresults,andthedesignshavenotbeenstrongforexaminingtheissueofantidepressantusageprecipitatingmania.Thestudieswithafollowupcomponent,highretentionandthemoststructuredassessmentsofmaniahavetendedtoproducethesmallesteffects.Overall,thesefindingsappearmostconsistentwiththeVigilanceandBipolardepressionhypotheses.TheMedicationasirrelevanthypothesisappearsatleastasplausibleasanyoftheIatrogenichypothesesbasedonthedata.

Clinicaltrials

SeveralresearchgroupshavereportedmaniaasanadverseeventduringbothopenlabelandRCTsexaminingSSRIsastreatmentforchildrenandadolescents.

Citalopram

Among174youthstreatedfordepressionwithcitalopramorplaceboinaRCT,nonedevelopedmania,althoughadverseeventswerereportedspontaneouslyandmaniawasnotformallyassessed[80].Inanopenlabeltrialofcitalopramtreatmentforearlyonsetmajordepressivedisorder(MDD),ShiraziandAlaghbandRadfoundthatoverthe6weekstudyperiod,16.7%ofchildrenandadolescentsexperiencedanunexpectedswitchtomania[81].Sincethedesignwasanopentrial,itisparticularlyvulnerabletotheVigilanceissueandbecausethereisnocomparisongroup,thefindingsdonotprovideinformationregardingincreaseofrisk[28].

Escitalopram

Of264childrenandadolescentstreatedwithescitalopramorplacebofordepression,onedevelopedmaniahowever,thisoccurredintheplacebocondition[82].Adverseeventreportingwasspontaneousorobservational.

Fluoxetine

PerhapsthebestknownstudyoffluoxetineforadolescentdepressionistheTreatmentofAdolescentDepression(TADS)trial[30].TheTADStrialspecificallyassessedforthedevelopmentofmanicsymptoms.Fluoxetinewasgiveneitheraloneorincombinationwithcognitivebehavioraltherapy.Foursubjects(3.67%)onfluoxetinealoneandone(0.93%)inthecombinationarmdevelopedsymptomsonthemaniaspectrumduringtreatment,versusoneonplaceboandnonein



thecognitivebehavioraltherapyonlyarm.However,threeofthefivewhodevelopedmaniabeganthetrialwithhighbaselinemaniasymptomscoresasassessedbytheAdolescentDepressionScale,developedspecificallyfortheTADStrial.Atotalof38patientsoverallbeganfluoxetinetreatmentwithhighbaselinemaniascorestherefore,most(92%)ofpatientsactuallytoleratedfluoxetinewellwithrespecttothedevelopmentofmaniaorhypomania.

Inanotherdoubleblind,randomized,placebocontrolledtrialoffluoxetinefordepressedchildrenandadolescents,6.25%(n=3)ofyouthsreceivingfluoxetineexperiencedamanicepisodeduringtreatmentversusarateof2%(n=1)onplacebo[83].Inasecondrandomized,placebocontrolledtrialoffluoxetineforyouthswithdepression,oneparticipantoutof109developedamanicreactionwhilenoparticipantsintheplacebogroup(n=110)did.Thisdifferencewasnotstatisticallysignificant[3].Intherelapsepreventionphaseofthistrial,therewerenoreportsofmaniaamong20patientsremainingonfluoxetine,althoughwhetheritwasspecificallyassessedforwasnotstated[84].Go,MalleyandBirmaherreportedthatduringopenlabelclinicaltreatment,30%of40youthswithobsessivecompulsivedisorder(OCD)andmooddisordersdevelopedmanicorhypomanicsymptomswhentreatedwithfluoxetineorsertraline[59].Becausethestudywasopenlabel,theVigilancehypothesisisamajorconcern.Owingtothecomorbidmooddisorders,theBipolardepressionhypothesisisalsoviable.

Fluvoxamine

An8weekRCToffluvoxaminetreatmentforanxietydisorders,aswellasa6monthopenlabelfollowuptrialof128participantsfromthe8weektrial,failedtoidentifyanyyouthsexperiencingmania[85,86].Neitherpublicationspecificallystatesthattherewasnooccurrenceofmania,norisitclearwhatassessmentstrategy,ifany,wasusedtoassessforhypomaniaormania.

Paroxetine

InaRCTofparoxetinetreatmentfor206childrenandadolescentswithMDD,adverseeventswere'gatheredbyspontaneousreport',andnoincidentsofmaniawerereported[7].Thedevelopmentofmaniawasnotspecificallyassessed.

Sertraline

McConvilleandcolleaguesfoundthatoneoutofeighthospitalizedadolescentswithMDDdevelopedmaniaduringopenlabelsertralinetreatment[87].WagnerandcolleaguesconductedtwolargetrialsofsertralinetreatmentforMDDinchildrenandadolescentshowever,thesetrialsfailedtospecificallyassessformania,andnonewasreported[4].WhensertralinewasusedtotreatOCDin137childrenandadolescents,bothduringa12weekrandomizedplacebocontrolledtrial[88]andduringa52weekopenlabelextensionstudy[89],noneoftheparticipantsexperiencedmanicorhypomanicsymptoms.ThesefindingsareconsistentwiththeBipolardepressionhypothesisthe'switch'tomaniaappearswhenpeoplehavedepression,butnotwhentheyaretreatedwithantidepressantsforotherconditions(e.g.,attentiondeficithyperactivitydisorder)[79].Thepatternsuggeststhatitisthedepression,nottheantidepressant,thatappearsmorelinkedtothemania,aswasalsothecaseintheTADStrial(seeabove).

Venlafaxine

IntheTreatmentofSSRIResistantDepressioninAdolescents(TORDIA)trial,oneparticipantoutof83randomizedtoreceivevenlafaxinedevelopedhypomania[31],assessedusingamaniascreenandtheManiaRatingScale.Inthesametrial,noparticipantsdevelopedmaniaamong168randomizedtoreceivefluoxetine,paroxetineorcitalopramand83randomizedtoreceivevenlafaxineincombinationwithcognitivebehavioraltherapy.

Theratesreportedhereformaniaasanadverseeventduringclinicaltrialsmayactuallyunderestimatethetruerisk,asparticipantswithafamilyhistoryofbipolardisorderwereexcludedfrommostofthesestudies.Hadthesetrialsincludedyouthswithahigherriskofexperiencingmaniaevenintheabsenceofexposuretoantidepressanttreatment,ratesofmaniaduringSSRItreatmentmighthavebeenhigher.Ironically,therealsoappearstobeaconfound,wherethestudieswithstrongerdesigns(randomized,blindedandplacebocontrolledtrials)mayhavehadlessthoroughorsystematicassessmentofmanicsymptoms,whereasopentrialsmayhavebeenmorevigilanttothepossibilityofmanicsymptoms.ItisagainunclearwhetherSSRItreatmentcausedthemanic/hypomanicsymptoms,orwhetherthesemayhaveemergednaturallyinthecourseofanexistingmooddisorder,buttheweightoftheevidenceappearstofavortheBipolardepressionhpothesismorethananyoftheIatrogenichypotheses(ignition,scarorsideeffect).

Riskversusbenefitanalysis

TheEvidenceBasedMedicineframework[28]alsoprovideswaysofquantifyingthestrengthofassociationbetweenantidepressantsandmania.Theseincludetherelativerisk(RRtheratiooftheratesofmaniaintheantidepressantexposedgroup,dividedbytherateinthenonantidepressantcomparisongroup),theoddsratio(oddsofmaniainthe



antidepressantgroupdividedbyoddsofmaniainthecomparisongroup)andthenumberneededtoharm(NNH).TheNNHisthereciprocalofthedifferenceintheratesofmaniaintheantidepressantexposedversuscomparisongroup.Conceptually,theNNHisthenumberofpatientsthatwouldneedtobeexposedtoantidepressantsbeforeonemoreonaveragewoulddevelopmania.TheNNHhasacorrespondingmeasureofthemagnitudeofbeneficialtreatmenteffects,thenumberneededtotreat(NNT)inorderforonemorepatienttohaveagoodoutcome.TheNNTandNNHcanbecombinedtocreatealikelihoodofhelpversusharm(LHHthereciprocalsoftheNNTdividedbythereciprocaloftheNNH,sothatlargernumbersindicategreaterprobabilityofbenefit).

Whatwouldthesemetricssuggestabouttherelationshipbetweenantidepressantsandmania?Wefocusonfluoxetineasanexample,because:first,fluoxetinehasthebestevidenceofefficacyforpediatricdepression[6]second,fluoxetineappearstobeassociatedwithsomewhathigherratesofmaniathanotherSSRIs[90]andthird,fluoxetinehasmultiplepublishedRCTswheretheratesofmaniacanbecomparedwithratesinarandomlyassignedplaceboarm,providingsomeofthebestevidenceavailableontheissue[3,59,83].PoolingtheresultsofthethreeRCTs,therateofmaniaonfluoxetinewas2.8%,versusarateof1.0%onplacebo.TheRRofmaniais2.8,approachingtherangewhereweshouldbeconcerned(RR3wouldbe'convincing')[28].TheNNHis56,meaningthatforevery56youthsexposedtofluoxetine,onaverageonemorewoulddevelopmania.TheNNHestimatedseparatelyforeachRCTrangedfrom24to145.Ontheotherhand,fluoxetineappearedefficaciousacrossallthreestudies,withNNTestimatesrangingfrom3.8to6.5,andapooledestimateof4.7.TheLHHis11.8whenallthreestudiesarecombined,andrangedfrom6to22forthestudiesseparately.Thus,whenfocusingonthecompoundwiththemostevidenceforefficacyandalsothegreatestconcernaboutmaniaasanadverseevent,patientsappearroughly12timesmorelikelytobenefitthantoexperiencemaniaandeventheworstcasescenarioisthatpatientswouldstillbesixtimesmorelikelytobenefit.EstimatingtheLHHseparatelyforseveralstudiesisonewayofconductinga'sensitivityanalysis',orexaminingtheextenttowhichtheLHHestimatechangesdependingonthestartingvalues.Sensitivityanalysescanalsoinclude'whatif'scenarios,wheretheLHHisrecalculatedusingmoreliberalorconservativeestimatesofrisk,sothatthedecisionmakerscanunderstandtheeffectsofchangingassumptionsonthefinalestimates[28].

ItispossibletofurthercustomizetheLHH,addingadditionalinformationaboutindividualfactorsaffectingtheprobabilityofriskorbenefit,aswellasincorporatingpatientpreferences.Strausetal.providedetailedexamplesofaddingthesefactorsintotheequation(seepage139143[28]).Onaverage,includingpatientpreferenceswilltypicallyshiftthebalanceevenfurtherinfavorofbenefitinsteadofharm.Twomajorreasonsforthisaretheevidencethatdepressioncreatesmoreburdenthanmania,andhasaworseeffectonqualityoflife[91]andalsobecausedepressionisthemorelethalphaseoftheillness(includingbeingamajorcomponentofmixedstates)[44].Italsomaybepossibletoshiftthebalancefurtherbyprovidingpsychoeducationtothefamily,usingcarefulmonitoringtodetectmania,andestablishingaplanformanagingmanicsymptomsshouldtheyemerge.Byincreasingtheknowledgeandtheexternalsupportsavailable,therisksassociatedwithmaniamaybemorecontained.Withclosemonitoring,itismorelikelythattreatmentcouldbechangedduringhypomaniaratherthanwaitinguntilfullblownmaniamanifests.Atthesametime,theirritablemoodandaggressionfrequentlyassociatedwithpediatricmaniaareoftenachiefconcernoffamiliesandamajortreatmenttarget[92],sointerventionsthatincreasetheriskofdisinhibited,aggressivebehaviormayrequiremorecaution.

Limitations

Thereareseveralimportantlimitationstokeepinmind,bothaboutthestateoftheliterature,andalsoaboutthisparticularreview.Decisivestudiesabouttherelationshipbetweenantidepressantsandmaniahavenotbeenconducted,soitisimpossibleforareviewtodrawdecisiveconclusions.Somelimitationsoftheliteratureinclude:

*Mostpublishedarticlesdonotsatisfymostofthecriteriaforprovidingavalidsourceofinformationaboutriskofharm[28].Casereportsarenotadequate,unlessperhapstheyusedrechallenge,ABABdesigns,buttheseareclinicallynotconducted.SeeBox1foralistoftheguidelinesandothercommentsonthestateoftheliterature

*Therearelargedifferencesintheratesofmaniaidentifiedacrossstudiesandinconsistenciesinthesizeofthefindings,makingitplausiblethatmethodologicalissues(suchastheVigilanceorFalseAlarmhypotheses)orthenaturalcourseofbipolardisorder(consistentwiththeMedicationasIrrelevantortheBipolarDepressionHypotheses)explainthefindings,insteadofoneoftheproposediatrogenicmechanisms

*Therearemajordifferencesintheoperationaldefinitionofmaniaacrossstudies,andequallylargedifferencesinhowmaniaisassessedThesemakeitmuchmoredifficulttointerpretfindings

*Theremaybelocalandhistoricalchangesinpatternsofdiagnosis.Thesteepincreasesintherateofbipolardiagnosesshowsthattherehavebeendramaticchangesinpracticethatareindependentofchangesinactualrateofincidence.Cliniciansmaybecomehypervigilanttothepossibilityofmania.Cognitiveheuristicsandpublicationbiasbothwillleadtooveremphasizingthedegreeofrisk



*Manychartreviewsandclinicaltrialsexcludedbipolaryouth.Wedonotknowratesofswitchingfortheseyouth(versusyouthwithanxietyorMDDthathasnotyetshownitselftobebipolar)[cf.76],althoughtheadultliteraturesuggestsitcouldbehigherthanwhatweareseeinghere.Conversely,studieswithyouthsexposedtoantidepressantswhodidnothaveahistoryofdepressionhaveconsistentlyfoundlowratesofmania[9395].Thetwocompetingexplanationsforthispatternoffindingsarethatassessmentofmaniainthesestudiesisnotsufficientlysystematictobesensitivetoinstancesthatactuallyareoccurring(avariantoftheVigilancehypothesis),orthatitispreviouslyundiagnosedbipolardisorderthatwasbeingtreatedfordepression,andthensubsequentlymanifesteditsassociatedmanicsymptoms(theBipolardepressionhypothesis).Theinsufficientsensitivityargumentislessofaconcerngiventhatoneofthestudiesfindingnoincreaseinriskwasasecondaryanalysisoflongitudinaldatafromoneoftheleadinginvestigationsofpediatricbipolardisorder[79].

Anadditionallimitationofthisreviewisthatitdoesnotattempttometaanalyzetheexistingstudies,relyinginsteadonqualitativewaysofappraisinganddescribingthefindings.Theliteraturedoesnotyetseemlargeenoughtosupportameaningfulmetaanalysis,particularlywithsofewstudiesreportingadequateinformationtoestimaterelativerisks.

Conclusions

Therehasbeenwidespreadconcernthatantidepressantsmightbeassociatedwithmania,bothatthelevelofindividualcasesandnowatthepublichealthlevel.MedicationexposureisoneofthepotentialfactorsunderdiscussionfortherisingratesofpediatricmaniaintheUSA[24].Practitionerswantclearguidanceabouttheriskssothattheycanavoidthepotentialharmoftriggeringmaniasinpatientswithdepression.Itisalsounclearwhetherantidepressantsshouldbeinthearmamentariumoftreatmentoptionsformanagingpediatricmooddisturbanceand,ifso,forwhichpatients.Theavailableliteratureiscomplexandinconsistent,makingitdifficulttoformaneducatedopinionquickly.

Thisreviewattemptstomovebeyonda'boxscore'approachoftallyingthenumberofstudiesfindingevidenceforantidepressantsinducingmaniaornot.Westartedbylayingoutsevendifferentmodelsofhowantidepressantscouldappeartobeassociatedwithmania.Threewerevariationsofiatrogenicmodels,whereantidepressantsmightigniteapreexistingdiathesisformania,createanewandlingeringriskformaniaorcreatemanicsymptomsasatemporarysideeffectofthecompound.Twoofthemodelspertaintothenaturalcourseoftheillness:onearguesthatmaniaoccursindependentofthemedication,thatantidepressantsareirrelevant(orperhapsevenslightlyprotective).ThesecondbuildsontheNaturalcourseHypothesisbypointingoutthatcliniciansaremostlikelytoencounterbipolarillnessduringthedepressedphase,thatthefirstphaserequiringtreatmentisalsooftendepressionandthatearlierageofonsetfordepressionappearstobeassociatedwithbipolardisorder.Inshort,aconstellationoffactorsmayberesultinginasubstantialportionofpediatricdepressionactuallybeingonthebipolarspectrum.Ironically,aconservativestanceaboutpediatricbipolardisordercouldresultinanunderestimationoftheriskfactorsandwarningsigns,leadingtoaninitialunderdiagnosisofbipolardisorderthatthenappearsto'switch'tomaniaasthepractitionerfollowsthepatient.Thefinaltwomodelsaremethodologicalartifactsthatareoftencalled'confounds'.Skepticsoftenraisethepossibilitythatpediatricbehavior'withinthenormallimits'ismistakenlypathologized.TheVigilancemodelholdsthatapparentchangesinratesofmaniaaredrivenbyshiftsinthesensitivityofclinicaldiagnoses.

Whatbecomesclearoverthecourseofthereviewisthattheiatrogenicmodelsarethemostprovocativeandthemethodologicalartifactsaretheleastlikelytocommandattention.However,theweightoftheevidenceappearstosuggestthatsomeoftheleaststirringordiscussedmodelsmayactuallyhavethemostsupport.Conversely,theiatrogenicmodelshavenotaccumulatedstrongevidencedespitethehighlevelofconcerntheyinviteandtheevidenceisweakestintheRCTsthathavethestrongestdesigns.

Onthebasisofthisreview,theconclusionistoproceedwithcaution.BasedontheLHHframeworkfromEvidenceBasedMedicine,antidepressantsappeartoofferaclearnetbenefitfortheaveragepatient.TheEvidenceBasedMedicineapproachalsoofferspractitionersawayofcustomizingandpersonalizingclinicaldecisions,takingintoaccountindividualriskfactorsandpreferences.Thescaleswilltipfurtherinfavorofantidepressantusageincaseswherethedepressionissevereorrefractory,andwheretherisksofmaniacanbecontainedbyprovidinggoodpsychoeducationtothefamilyanddeployingcarefulassessmenttoolsthatwillbesensitivetotheemergenceofmaniaorsideeffects.Incaseswherethereisafamilyhistoryofbipolardisorder,orcaseswithahistoryofimpulsiveaggressivebehavior,thenthebalancewouldshiftawayfromSSRIusage(althoughtheevidenceofharmisnotmuchmorewellfoundedforthesecasesthanformaniaingeneral).

Futureperspective

Therearemanywaysthatthesituationwillimproveoverthenext5to10years.Theclinicalconcernthatantidepressantsmightinducemaniahasraisedawarenesstothepointthatfuturestudiesusingantidepressantsmaydothesystematicassessmentofmanicsymptomsbothlifetimehistorypriortoenrollment,aswellaslookingforemergenceduringtreatmentneededtodecisivelyaddresstheissue.Improvedassessedtoolsarealreadyavailable(see[96]forreviewanddiscussionaboutimplementation),andiftheyareadoptedmoreinresearchandclinicalpracticetherewillbeimmediateimprovementsinthemanagementofpediatricmooddisorder.Inthenearfuture,therewillbecontributionsfromthe


http://go.galegroup.com.vlib.interchange.at/ps/retrieve.do?sgHitCountType=None&sort=RELEVANCE&docType=Report&prodId=AONE&tabID=T002&s 10/17

personalizedmedicinevantagetoo,withimprovedassessmentintermsofgenotyping(includingidentificationofindividualdifferencesinresponsetomedication)[97],metabolicmeasuresofphysiologicalresponsetomedication,andtheuseofnoninvasivetechnologies(suchasactimetryorcellphonebasedlifecharting)toprovidemorerapidandobjectivemeasuresofmoodchange.Althoughtheissueofantidepressantsandmaniahasbeencomplexandcontentiousinthepast,researchisbeginningtomakecontributionstoevidencebasedtreatment,andthepacewillacceleraterapidly.

Box1.Criteriaforevaluatingwhetherevidenceaboutantidepressantinducedmaniaisvalid.Criterion Evaluationoftheliterature

1.Werethereclearlydefinedpatientgroupsthatweresimilarinallwaysotherthanexposuretoanantidepressant?

Nocomparisongroupincasestudies.Comparisongroupsdifferacrossotherstudies.

2.Weretreatmentsandmanicsymptomsmeasuredthesamewayinbothgroups?Wastheassessmentofmaniaobjectiveorblindedtoantidepressantexposurestatus?

Openlabeltrialsandcasestudiesnotblinded.

3a.Wasthefollowupperiodsufficientlylongformaniatooccur? Variable,butoftensufficient(extendingouttoayearormore).

3b.Wasretentionadequate?Howweremissingdatatreated?

Strausetal.[28]offeraruleofthumbofignoringanystudywithmorethan20%losttofollowup,becausethiswilllikelyintroducebias.Missingdataareoftennotdiscussedinpublishedreportsonantidepressantsandmania.

4.Dotheresultssatisfysomeofthediagnostictestsforantidepressantscausingmania?4a.Isitclearthatantidepressantexposureprecededtheonsetoftheoutcome?

Ifassessmentofmaniaisnotrigorousatbaseline,thenpriorhypomaniacanescapedetection.

4b.Isthereadoseresponsegradient? Doseresponsehasnotbeendemonstratedforantidepressantinductionofmaniayet.4c.Isthereanypositiveevidencefromawithdrawalrechallengestudy?

Wehavenotfoundarechallengestudyintheliterature.Thereisablindedwithdrawalstudy[98].

4d.Istheassociationbetweenantidepressantsandmaniaconsistentfromstudytostudy?

No.Resultsrunthefullgamutfromincreasedratesofmania,tonodifferenceinrates,tosignificantdecreasesinratesofmania.

4e.Doestheassociationbetweenantidepressantsandmaniamakebiologicalsense? Yes,clearly.

Adaptedfrom[28].

Executivesummary

Background

*Thedecisivestudytoestablishtheriskofanantidepressanthasnotbeenconducted.Thiswouldrequireadoubleblinded,placebocontrolledtrialwithexcellentassessmentofmanicsymptoms,includingalifetimehistorypriortorandomization,andalongenoughfollowuptocapturethemajorityofsubsequentmanicevents.

*Antidepressantinducedmaniainadultsisagenerallyacceptedclinicalphenomenon,evenintheabsenceofsuchadecisivestudy.

*Theexistingliteratureregardingpediatricantidepressantusageandmaniaisalmostentirelybasedondesignspronetobias.

Modelsoftherelationshipbetweenantidepressants&mania(&sevenpotentialpitfalls&remediesforpractitioners)

*Ignitionhypothesisuncoveringalatentdiathesis,turningongenesthatwerealreadypresent.Althoughofgreatconcern,thereislittlesupportingevidenceforthisfromstudieswithstrongerresearchdesigns.

*Scarhypothesiscreatinganewdiathesisintheabsenceofpriorbiologicalrisk.Thisisperhapsthemostworrisomehypothesis,andalsooneofthemostspeculative,withnodirectsupportingevidenceyetintheliterature.

*Sideeffecthypothesistemporarydeleteriouseffectofdrug,butnotatruemanifestationofabipolarillness.Thishypothesisappearstobeplausible,buttheeffectsappeartoberareinstudieswithstrongdesigns.

*Vigilancehypothesisincreasedmonitoringfortheillness,butnoactualchangeinrisk.Thishypothesisislikelyto



contributetothehighratesofmaniaobservedinopentrials,whichironicallyoftenhaveusedbettermonitoringofmanicsymptomsthanmanyoftheblinded,randomized,controlledtrials.

*Medicationasirrelevanthypothesiswhatwearewitnessingisthenaturalcourseofthebipolarillness,notaresponsetothetreatment.Thishypothesisappearsconsistentwithlongitudinaldataaboutcourseofillnessandepidemiologicaldataitcanalsoaccountformuchoftheapparentlyhighrateofmanicsymptomsemergingduringthecourseoftreatmentformooddisorders.

*Falsealarmshypothesismislabelingjuvenilebehavioraspathologicalwhenitstillfallswithinnormallimitsmistakingirritabilityduetoothercausesasanindicatorofpediatricmaniaoralternately,mistakingthereturnofenergyandpositiveemotionsasdepressionliftsforhypomania.Thisisalsoaplausiblehypothesis,especiallygivenemergingevidenceoflargedifferencesindiagnosticformulationsforsimilarsymptompresentationsacrosspractitioners,clinicsandevencountries.

*Bipolardepressionhypothesiswhentreatingyouthsfordepression,weareoftendealingwiththedepressedphaseofwhatwillprovetobeabipolarillness.Thisappearstobealikelycontributortotheratesofmanianotedduringtreatmentofmood,andactuallycouldexplainseeminglyhigherratesinyouthsthanadultsbecauseofthepossibilitythatbipolardepressionwillbethefirstphaseofillnesstodrivetreatmentseeking.

Reviewoftheevidenceforantidepressantspotentiallyinducingmania

*Casestudiesofselectiveserotoninreuptakeinhibitor(SSRI)inducedmaniainyouthsarecommon,butaddlittleevidenceabouthowpatientsshouldbetreated.Casestudiesarebiased'youthonantidepressantsfailstobecomemanic'isunlikelytobepublished.

*PublishedchartreviewstudiesofSSRIcoincidentmaniagenerallyfailtomeetguidelinesfordemonstratingclearevidenceofharm.

*Clinicaltrialsexistformostoftheantidepressantsusedwithyouthshowever,theassessmentandreportingofmanicsymptomswasnotrigorousinolderstudies.Thiscouldleadtounderestimatingabsoluteratesofmania,butshouldnotbiasestimatesofrelativeriskforantidepressantsversusplacebo.

Riskversusbenefitanalysis

*Depressionisworsethanmaniaintermsofburdenontheindividualandriskofsuicide.Thegreaterriskandburdenmaytipthescaleinfavorofcontinuingtouseantidepressantstomanagethedepression,withclosemonitoringformania.

*Fluoxetinehasthebestcurrentdataabouttreatmentefficacy,andalsosomeofthegreatestconcernsaboutpotentialassociatedmania.Basedonthreerandomizedtrials,thelikelihoodofhelpversusharm(mania)onfluoxetineismorethan11,favoringantidepressantuse,beforeconsideringpatientcharacteristicsorpreferences.

Limitations

*Decisivestudieshavenotbeencarriedout.Theliteraturedoesnotsupportaclear'finalanswer'abouttherelationshipbetweenantidepressantsandmania.

Conclusions

*Proceedwithcaution.Despitethegreatconcernaboutthepossibilityofantidepressantsincreasingtheriskofmania,thestudieswiththestrongestresearchdesignsfindthesmallestevidenceofrisk.

*Patientsonfluoxetinearemorethantentimesmorelikelytobenefitthanexperiencemania.Takingpatientpreferencesintoaccountwilloftentipscalesfurthertowardsantidepressantusagetomanagemood.

*Educationaboutmedicationandsideeffectsandcarefulmonitoringformaniawillfurthercontainrisks.

Futureperspective

*Personalizedapproachestomedicine,includinggeneticandmetabolictestingaswellastechnologicalimprovementsinassessmentofmoodandenergy,willsoonprovidepowerfultoolstohelpgaugeriskandresponsetoantidepressantsaswellasothertreatmentregimens.

Bibliography

Papersofspecialnotehavebeenhighlightedas:*ofinterest**ofconsiderableinterest



1KratochvilCJ,VitielloB,WalkupJetal.:Selectiveserotoninreuptakeinhibitorsinpediatricdepression:isthebalancebetweenbenefitsandrisksfavorable?J.ChildAdolesc.Psychopharmacol.16,1124(2006).

2OlfsonM,MarcusSC,WeissmanMM,JensenPS:Nationaltrendsintheuseofpsychotropicmedicationsbychildren.J.Am.Acad.Child.Adolesc.Psychiatry41,514521(2002).

3EmslieGJ,HeiligensteinJH,WagnerKDetal.:Fluoxetineforacutetreatmentofdepressioninchildrenandadolescents:aplacebocontrolled,randomizedclinicaltrial.J.Am.Acad.ChildAdolesc.Psychiatry41,12051215(2002).

4WagnerKD,AmbrosiniP,RynnMetal.:Efficacyofsertralineinthetreatmentofchildrenandadolescentswithmajordepressivedisorder:tworandomizedcontrolledtrials.JAMA290,10331041(2003).

5MichaelKD,CrowleySL:Howeffectivearetreatmentsforchildandadolescentdepression?Ametaanalyticreview.Clin.Psychol.Rev.22,247269(2002).

6UsalaT,ClavennaA,ZuddasA,BonatiM:Randomisedcontrolledtrialsofselectiveserotoninreuptakeinhibitorsintreatingdepressioninchildrenandadolescents:asystematicreviewandmetaanalysis.Eur.Neuropsychopharmacol.18,6273(2008).

7EmslieGJ,WagnerKD,KutcherSetal.:Paroxetinetreatmentinchildrenandadolescentswithmajordepressivedisorder:arandomized,multicenter,doubleblind,placebocontrolledtrial.J.Am.Acad.ChildAdolesc.Psychiatry45,709719(2006).

8RenaudJ,AxelsonD,BirmaherB:Ariskbenefitassessmentofpharmacotherapiesforclinicaldepressioninchildrenandadolescents.DrugSafety20,5975(1999).

9BridgeJA,IyengarS,SalaryCBetal.:Clinicalresponseandriskforreportedsuicidalideationandsuicideattemptsinpediatricantidepressanttreatment:ametaanalysisofrandomizedcontrolledtrials.JAMA297,16831696(2007).

10ClennellA:Threatofsuicideleadstobanofmajorantidepressantsforchildren.TheIndependent.10December2003.

11BaumerFM,HoweM,GallelliK,SimeonovaDI,HallmayerJ,ChangKD:Apilotstudyofantidepressantinducedmaniainpediatricbipolardisorder:characteristics,riskfactors,andtheserotonintransportergene.Biol.Psychiatry60,10051012(2006).

12HellanderM:Medicationinducedmania:ethicalissuesandtheneedformoreresearch.J.ChildAdolesc.Psychopharmacol.13,199(2003).

*Interestingeditorialthatnicelyoutlinesthecurrentdilemmasinunderstandingantidepressantcoincidentmania.

13CarlsonGA:Thebottomline.J.ChildAdolesc.Psychopharmacol.13,115118(2003).

14GoldbergJF,TrumanCJ:Antidepressantinducedmania:anoverviewofcurrentcontroversies.BipolarDisord.5,407420(2003).

15PapolosDF:Switching,cycling,andantidepressantinducedeffectsoncyclefrequencyandcourseofillnessinadultbipolardisorder:abriefreviewandcommentary.J.ChildAdolesc.Psychopharmacol.13,165171(2003).

16ElMallakhRS,KarippotA:Useofantidepressantstotreatdepressioninbipolardisorder.Psychiatr.Serv.53,580584(2002).

*Antidepressantcoincidentmaniaratesinadults.

17TrumanCJ,GoldbergJF,GhaemiSNetal.:Selfreportedhistoryofmanic/hypomanicswitchassociatedwithantidepressantuse:datafromtheSystematicTreatmentEnhancementProgramforBipolarDisorder(STEPBD).J.Clin.Psychiatry68,14721479(2007).

18MartinA,YoungC,LeckmanJF,MukonoweshuroC,RosenheckR,LeslieD:Ageeffectsonantidepressantinducedmanicconversion.Arch.Pediatr.Adolesc.Med.158,773780(2004).

19BaldessariniRJ,FaeddaGL,HennenJ:Riskofmaniawithantidepressants.Arch.Pediatr.Adolesc.Med.159,298authorreply298299(2005).

20AltshulerLL,PostRM,LeverichGS,MikalauskasK,RosoffA,AckermanL:Antidepressantinducedmaniaandcycleacceleration:acontroversyrevisited.Am.J.Psychiatry152,11301138(1995).



21DavidowJ,LevinsonEM:Heuristicprinciplesandcognitivebiasindecisionmaking:implicationsforassessmentinschoolpsychology.Psychol.Sch.30,351361(1993).

22BladerJC,CarlsonGA:IncreasedratesofbipolardisorderdiagnosesamongU.S.child,adolescent,andadultinpatients,19962004.Biol.Psychiatry62,107114(2007).

23MorenoC,LajeG,BlancoC,JiangH,SchmidtAB,OlfsonM:Nationaltrendsintheoutpatientdiagnosisandtreatmentofbipolardisorderinyouth.Arch.Gen.Psychiatry64,10321039(2007).

24ReichartCG,NolenWA:Earlieronsetofbipolardisorderinchildrenbyantidepressantsorstimulants?Anhypothesis.J.Affect.Disord.78,8184(2004).

25SpraggsC,McCarthyA,McCarthyLetal.:GeneticvariantsintheepithelialsodiumchannelassociatewithoedemainType2diabeticpatientsreceivingtheperoxisomeproliferatoractivatedreceptorgagonistfarglitazar.Pharmacogenet.Genomics17,10651076(2007).

26DiagnosticandStatisticalManualofMentalDisorders(4thTextRevisionEdition).AmericanPsychiatricAssociation,Washington,DC,USA886(2001).

27KraemerHC,LoweKK,KupferDJ:ToYourHealth:HowtoUnderstandWhatResearchTellsUsAboutRisk.OxfordUniversityPress,NY,USA288(2005).

28StrausSE,RichardsonWS,GlasziouP,HaynesRB:EvidenceBasedMedicine:HowtoPracticeandTeachEBM(3rdEdition).ChurchillLivingstone,NY,USA(2005).

*Definitivehandbookofevidencebasedmedicine.

29GarbHN:StudyingtheClinician:JudgmentResearchandPsychologicalAssessment.AmericanPsychologicalAssociation,Washington,DC,USA(1998).

30EmslieG,KratochvilC,VitielloBetal.:TreatmentforAdolescentswithDepressionStudy(TADS):safetyresults.J.Am.Acad.ChildAdolesc.Psychiatry45,14401455(2006).

**Theseauthorsdoanexcellentjobofdiscussinghowtheyassessedformaniaintheirtrialandwhattheimplicationsoftheratesofmaniawere.

31BrentD,EmslieG,ClarkeGetal.:SwitchingtoanotherSSRIortovenlafaxinewithorwithoutcognitivebehavioraltherapyforadolescentswithSSRIresistantdepression:theTORDIArandomizedcontrolledtrial.JAMA299,901913(2008).

32CampbellDT,StanleyJC:ExperimentalandQuasiExperimentalDesignsforResearch.HoughtonMifflin,MA,USA84(1963).

33MoherD,SchulzKF,AltmanDG:TheCONSORTstatement:revisedrecommendationsforimprovingthequalityofreportsofparellelgrouprandomisedtrials.Lancet357,11911194(2001).

34MerikangasKR,HerrellR,SwendsenJ,RosslerW,AjdacicGrossV,AngstJ:Specificityofbipolarspectrumconditionsinthecomorbidityofmoodandsubstanceusedisorders:resultsfromtheZurichcohortstudy.Arch.Gen.Psychiatry65,4752(2008).

35DubickaB,CarlsonGA,VailA,HarringtonR:Prepubertalmania:diagnosticdifferencesbetweenUSandUKclinicians.Eur.ChildAdolesc.Psychiatry17,153161(2008).

36HealyD:Thelatestmania:sellingbipolardisorder.PLoSMedicine3,E185(2006).

37BiedermanJ,MickE,FaraoneSV,SpencerT,WilensTE,WozniakJ:Currentconceptsinthevalidity,diagnosisandtreatmentofpaediatricbipolardisorder.Int.J.Neuropsychopharmacol.6,293300(2003).

38GellerB,TillmanR:PrepubertalandearlyadolescentbipolardisorderI:reviewofdiagnosticvalidationbyRobinsandGuzecriteria.J.Clin.Psychiatry66(Suppl.7),2128(2005).

39YoungstromEA,BirmaherB,FindlingRL:Pediatricbipolardisorder:validity,phenomenology,andrecommendationsfordiagnosis.BipolarDisord.10,194214(2008).

40BirmaherB,RyanND,WilliamsonDEetal.:Childhoodandadolescentdepression:areviewofthepast10years.PartI.J.Am.Acad.ChildAdolesc.Psychiatry35,14271439(1996).



41GellerB,ZimermanB,WilliamsM,BolhofnerK,CraneyJL:BipolardisorderatprospectivefollowupofadultswhohadprepubertalmajorDepressivedisorder.Am.J.Psychiatry158,125127(2001).

42LishJD,DimeMeenanS,WhybrowPC,PriceRA,HirschfeldRM:TheNationalDepressiveandManicDepressiveAssociation(DMDA)surveyofbipolarmembers.J.Affect.Disord.31,281294(1994).

43GoodwinFK,JamisonKR:ManicDepressiveIllness(2ndEdition).OxfordUniversityPress,NY,USA1262(2007).

44PerlisRH,BrownE,BakerRW,NierenbergAA:Clinicalfeaturesofbipolardepressionversusmajordepressivedisorderinlargemulticentertrials.Am.J.Psychiatry163,225231(2006).

45GuyattGH,RennieD(Eds):Users'GuidestotheMedicalLiterature.AMAPress,IL,USA706(2002).

46PeetM:Inductionofmaniawithselectiveserotoninreuptakeinhibitorsandtricyclicantidepressants.Br.J.Psychiatry164,549550(1994).

47HenryC,SorbaraF,LacosteJ,GindreC,LeboyerM:Antidepressantinducedmaniainbipolarpatients:identificationofriskfactors.Clin.Psychiatry62,249255(2001).

48GhaemiSN,BoimanEE,GoodwinFK:Diagnosingbipolardisorderandtheeffectofantidepressants:anaturalisticstudy.J.Clin.Psychiatry61,804808quiz809(2000).

49BirmaherB,AxelsonD,StroberMetal.:Clinicalcourseofchildrenandadolescentswithbipolarspectrumdisorders.Arch.Gen.Psychiatry63,175183(2006).

50PostRM:Theimpactofbipolardepression.J.Clin.Psychiatry66(Suppl.5),510(2005).

51HirschfeldRM:Bipolardepression:therealchallenge.Eur.Neuropsychopharmacol.14(Suppl.2),S83S88(2004).

52FindlingRL,ReedMD,BlumerJL:Pharmacologicaltreatmentofdepressioninchildrenandadolescents.Paediatr.Drugs1,161182(1999).

53AmeenS,JagadheesanK,SinhaVK:Citalopraminducedmanicswitchinanadolescentwithepilepsy.Aust.NZJ.Psychiatry37,776777(2003).

54PravinD,SrinathS,GirimajiS,SeshadriSP:Citalopramandmania.J.Am.Acad.ChildAdolesc.Psychiatry43,791(2004).

55AchamallahNS,DeckerDH:Maniainducedbyfluoxetineinanadolescentpatient.Am.J.Psychiatry148,1404(1991).

56JafriAB,GreenbergWM:Fluoxetinesideeffects.J.Am.Acad.ChildAdolesc.Psychiatry30,852(1991).

57VenkataramanS,NaylorMW,KingCA:Maniaassociatedwithfluoxetinetreatmentinadolescents.J.Am.Acad.ChildAdolesc.Psychiatry31,276281(1992).

58JeromeL:Hypomaniawithfluoxetine.J.Am.Acad.ChildAdolesc.Psychiatry30,850851(1991).

59GoFS,MalleyEE,BirmaherB,RosenbergDR:Manicbehaviorsassociatedwithfluoxetineinthree12to18yearoldswithobsessivecompulsivedisorder.J.ChildAdolesc.Psychopharmacol.8,7380(1998).

60DilerRS,AvciA:SSRIinducedmaniainobsessivecompulsivedisorder.J.Am.Acad.ChildAdolesc.Psychiatry38,67(1999).

61GrubbsJH:SSRIinducedmania.J.Am.Acad.ChildAdolesc.Psychiatry36,445(1997).

62OldroydJ:Paroxetineinducedmania.J.Am.Acad.ChildAdolesc.Psychiatry36,721722(1997).

63SharkeyL,O'DonovanA:Paroxetineinducedmaniainpreadolescence.Ir.J.Psychol.Med.21,3031(2004).

64GhaziuddinM:Maniainducedbysertralineinaprepubertalchild.Am.J.Psychiatry151,944(1994).

65HeimannSW,MarchJS:SSRIinducedmania.J.Am.Acad.ChildAdolesc.Psychiatry35,4(1996).

66KatH:MoreonSSRIinducedmania.J.Am.Acad.ChildAdolesc.Psychiatry35,975(1996).



67JamesAC:Casereport:MixedmaniaApparentinductioninanadolescentbyaselectiveserotoninreuptakeinhibitorantidepressant(SSRI).Clin.ChildPsychol.Psychiatry1,621624(1996).

68RamanRP,MathSB,GangadharBN:Venlafaxineinducedmanicswitchinanadolescentpatient:acasereport.Prim.CareCompanionJ.Clin.Psychiatry9,470(2007).

69GigerenzerG:Theadaptivetoolbox:towardadarwinianrationality.Nebr.Symp.Motiv.47,113143(2001).

70FaeddaGL,BaldessariniRJ,GlovinskyIP,AustinNB:Treatmentemergentmaniainpediatricbipolardisorder:aretrospectivecasereview.J.Affect.Disord.82,149158(2004).

71BiedermanJ,MickE,SpencerTJ,WilensTE,FaraoneSV:Therapeuticdilemmasinthepharmacotherapyofbipolardepressionintheyoung.J.ChildAdolesc.Psychopharmacol.10,185192(2000).

72WilensTE,BiedermanJ,KwonAetal.:Asystematicchartreviewofthenatureofpsychiatricadverseeventsinchildrenandadolescentstreatedwithselectiveserotoninreuptakeinhibitors.J.ChildAdolesc.Psychopharmacol.13,143152(2003).

73CiceroD,ElMallakhRS,HolmanJ,RobertsonJ:Antidepressantexposureinbipolarchildren.Psychiatry66,317322(2003).

74CarlsonGA,MickE:Druginduceddisinhibitioninpsychiatricallyhospitalizedchildren.J.ChildAdolesc.Psychopharmacol.13,153163(2003).

75DelBelloMP,HansemanD,AdlerCM,FleckDE,StrakowskiSM:Twelvemonthoutcomeofadolescentswithbipolardisorderfollowingfirsthospitalizationforamanicormixedepisode.Am.J.Psychiatry164,582590(2007).

76PaganoME,DemeterCA,FaberJE,CalabreseJR,FindlingRL:InitiationofstimulantandantidepressantmedicationandclinicalpresentationinjuvenilebipolarIdisorder.BipolarDisord.10,334341(2008).

77SoutulloCA,DelBelloMP,OchsnerJEetal.:Severityofbipolarityinhospitalizedmanicadolescentswithhistoryofstimulantorantidepressanttreatment.J.Affect.Disord.70,323327(2002).

78DelBelloMP,CarlsonG,TohenM,BrometEJ,SchwiersML,StrakowskiSM:Ratesandpredictorsofdevelopingamanicorhypomanicepisode1to2yearsfollowingafirsthospitalizationformajordepressionwithpsychoticfeatures.J.ChildAdolesc.Psychopharmacol.13,173185(2003).

79TillmanR,GellerB:Controlledstudyofswitchingfromattentiondeficit/hyperactivitydisordertoaprepubertalandearlyadolescentbipolarIdisorderphenotypeduring6yearprospectivefollowup:rate,risk,andpredictors.Dev.Psychopathol.18,10371053(2006).

80WagnerKD,RobbAS,FindlingRL,JinJ,GutierrezMM,HeydornWE:Arandomized,placebocontrolledtrialofcitalopramforthetreatmentofmajordepressioninchildrenandadolescents.Am.J.Psychiatry161,10791083(2004).

81ShiraziE,AlaghbandRadJ:Anopentrialofcitalopraminchildrenandadolescentswithdepression.J.ChildAdolesc.Psychopharmacol.15,233239(2005).

82WagnerKD,JonasJ,FindlingRL,VenturaD,SaikaliK:Adoubleblind,randomized,placebocontrolledtrialofescitalopraminthetreatmentofpediatricdepression.J.Am.Acad.ChildAdolesc.Psychiatry45,280288(2006).

83EmslieGJ,RushAJ,WeinbergWAetal.:Adoubleblind,randomized,placebocontrolledtrialoffluoxetineinchildrenandadolescentswithdepression.Arch.Gen.Psychiatry54,10311037(1997).

84EmslieGJ,HeiligensteinJH,HoogSLetal.:Fluoxetinetreatmentforpreventionofrelapseofdepressioninchildrenandadolescents:adoubleblind,placebocontrolledstudy.J.Am.Acad.ChildAdolesc.Psychiatry43,13971405(2004).

85WalkupJ,LabellarteM,RiddleMAetal.:Treatmentofpediatricanxietydisorders:anopenlabelextensionoftheresearchunitsonpediatricpsychopharmacologyanxietystudy.J.ChildAdolesc.Psychopharmacol.12,175188(2002).

86Fluvoxamineforthetreatmentofanxietydisordersinchildrenandadolescents.TheResearchUnitonPediatricPsychopharmacologyAnxietyStudyGroup.N.Engl.J.Med.344,12791285(2001).

87McConvilleBJ,MinneryKL,SorterMT,WestSA,FriedmanLM,ChristianK:Anopenstudyoftheeffectsofsertralineonadolescentmajordepression.J.ChildAdolesc.Psychopharmacol.6,4151(1996).



88MarchJS,BiedermanJ,WolkowRetal.:Sertralineinchildrenandadolescentswithobsessivecompulsivedisorder:amulticenterrandomizedcontrolledtrial.JAMA280,17521756(1998).

89CookEH,WagnerKD,MarchJSetal.:Longtermsertralinetreatmentofchildrenandadolescentswithobsessivecompulsivedisorder.J.Am.Acad.ChildAdolesc.Psychiatry40,11751181(2001).

90CheungAH,EmslieGJ,MayesTL:Reviewoftheefficacyandsafetyofantidepressantsinyouthdepression.J.ChildPsychol.Psychiatry46,735754(2005).

91FreemanAJ,YoungstromEA,MichalakEE,SiegelR,MeyersOI,FindlingRL:Qualityoflifeinpediatricbipolardisorder.Pediatrics(2009)(Epubaheadofprint).

92WozniakJ,BiedermanJ,KwonAetal.:Howcardinalarecardinalsymptomsinpediatricbipolardisorder?Anexaminationofclinicalcorrelates.Biol.Psychiatry58,583588(2005).

88MarchJS,EntusahAR,RynnM,AlbanoAM,TourianKA:ArandomizedcontrolledtrialofvenlafaxineERversusplaceboinpediatricsocialanxietydisorder.Biol.Psychiatry62,11491154(2007).

94MarchJS,FranklinME,LeonardHetal.:Ticsmoderatetreatmentoutcomewithsertralinebutnotcognitivebehaviortherapyinpediatricobsessivecompulsivedisorder.Biol.Psychiatry61,344347(2007).

95YoungstromE,MashEJ,BarkleyRA:Pediatricbipolardisorder.In:AssessmentofChildhoodDisorders(4thEdition).GuilfordPress,NY,USA253304(2007).

96MrazekDA:Currentapplicationsofclinicalgenetictestingforpsychiatricpractice.Minn.Med.90,4243(2007).

97WellerEB,WellerRA:Fluoxetinetopreventrelapseofdepressioninchildrenandadolescents.Curr.PsychiatryRep.8,8889(2006).

Websites

101Classsuicidalitylabelinglanguageforantidepressants.www.fda.gov/Cder/drug/antidepressants/PI_template.pdf(Accessed27July2008).

102WatersR:Johnnygetyourpills:areweovermedicatingourkids?(1999).http://dir.salon.com/story/health/feature/1999/06/17/antidepressants

AuthorAffiliation(s):

1UniversityofNorthCarolinaChapelHill,DepartmentofPsychology,CB#3270,DavieHall,ChapelHill,NC27599,[email protected]

2UniversityofNorthCarolinaChapelHill,DepartmentofPsychology,CB#3270,DavieHall,ChapelHill,NC27599,[email protected]

3UniversityofNorthCarolinaChapelHillSchoolofMedicine,DepartmentofPsychiatry,CB#7160,10612NeurosciencesHospital,101ManningDrive,ChapelHill,NC27599,[email protected]

AuthorNote(s):

[dagger]Authorforcorrespondence

Financial&competinginterestsdisclosure

ThisresearchwaspartlysupportedbyNIHR01MH69774(Soares),RR20571(Soares),aswellasNIHR01MH066647(Youngstrom).MeganFJoseph,MA,andEricAYoungstrom,PhD,havenofinancialrelationshipswithanypharmaceuticalcompany.JairSoares,MD,isonthespeaker'sbureauatEliLillyandAstraZeneca,isaconsultantforOrganonandShire,andreceivesgrantfundingfromPfizerandGlaxoSmithKline.Theauthorshavenootherrelevantaffiliationsorfinancialinvolvementwithanyorganizationorentitywithafinancialinterestinorfinancialconflictwiththesubjectmatterormaterialsdiscussedinthemanuscriptapartfromthosedisclosed.

Nowritingassistancewasutilizedintheproductionofthismanuscript.

MeganFJoseph,EricAYoungstrom,JairCSoares

SourceCitation(MLA7thEdition)



Joseph,MeganF,JairCSoares,andEricAYoungstrom."Antidepressantcoincidentmaniainchildrenandadolescentstreatedwithselectiveserotoninreuptakeinhibitors."FutureNeurology4.1(2009):87+.AcademicOneFile.Web.26Apr.2015.

URLhttp://vlib.interchange.at/login?url=http://go.galegroup.com/ps/i.do?id=GALE%7CA224881914&v=2.1&u=wash89460&it=r&p=AONE&sw=w&asid=1b8f0445a316c5d992b5c8d6765c5dad

GaleDocumentNumber:GALE|A224881914